High-dose rifapentine treatment for pregnant and breastfeeding people with TB
Rifapentine in High Doses in Pregnancy with TB (Radiant-Moms) study
This project tests whether higher-dose rifapentine can be a safe, shorter TB treatment option for pregnant and breastfeeding people, including those with HIV.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11400224 on NIH RePORTER |
What this research studies
You would be asked about your preferences and concerns around TB treatment during pregnancy and breastfeeding using surveys and choice-based questions. The team will use a discrete choice experiment to find what matters most to pregnant and breastfeeding people and to the healthcare providers who care for them, such as dosing, safety for the baby, and treatment length. The study focuses on people in places where TB is common and aims to gather real-world views to guide future dosing and safety studies. Your responses could help change who is included in TB treatment research and what treatment options become available.
Who could benefit from this research
Good fit: Pregnant or breastfeeding people diagnosed with TB—especially those living in high-TB-burden regions and people living with HIV—would be the ideal participants for the preference surveys.
Not a fit: People who are not pregnant or breastfeeding, do not have TB, or need immediate clinical treatment decisions are unlikely to get direct clinical benefit from this survey-based research.
Why it matters
Potential benefit: If successful, this work could help make shorter, safer TB regimens more acceptable and accessible for pregnant and breastfeeding people, reducing maternal and infant harm.
How similar studies have performed: Discrete choice experiments have been used successfully to measure treatment preferences in other conditions, but applying them to include pregnant and breastfeeding people in TB regimen decisions is relatively novel.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Hirsch-Moverman, Yael R — Columbia University Health Sciences
- Study coordinator: Hirsch-Moverman, Yael R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.